Emerging Genomic Biomarkers: Impact on Drug Discovery and Clinical Practice

1 post / 0 new
Tony Rook
Tony Rook's picture
Emerging Genomic Biomarkers: Impact on Drug Discovery and Clinical Practice

Emerging Genomic Biomarkers: Impact on Drug Discovery and Clinical Practice (Z3)
Organizers: Stephen H. Friend, Lawrence J. Lesko and Daniel K. Burns
May 7 - 11, 2006 Fairmont Empress Victoria Victoria, BC

http://www.keystonesymposia.org/Meetings/viewMeetings.cfm?MeetingID=770&subTab=program

Meeting Summary

This conference will focus on bringing together the developers of genomic technologies with the clinicians expecting to use them, and the regulators charged with ensuring their appropriate usage. We will focus on two themes. The first theme will be to exemplify how diverse methods to track DNA, RNA, and protein changes have come to rely on sophisticated techniques of pattern recognition bringing up questions of how best to validate these methods. The second theme is to contrast the strategies needed to develop disease phenotyping marker from those needed for intermediate response markers and from other markers such as predictive markers.

Upon completion of this meeting, participants should be able:

* To describe the economic considerations of biomarkers.
* To identify drug responders from non-responders
* To summarize the differences in the strategies needed to develop disease phenotyping markers, from intermediate response markers, from other markers such as predictive markers.
* To describe the methods utilized to track DNA, RNA, and protein changes.

Registration Deadlines and Pricing
NOTE: Please use buttons in blue bar above to Register Yourself, or to Register a Colleague

* You may register for this meeting on this web site until May 7, 2006.
* The Registration Fee includes the Abstract Submission Fee.
* For more information and other registration options, see How to Register.